One of them is to treat arthritis.. “World Health” agrees to two treatments C

0
33


Based on new data from clinical trials, it benefits patients with severe or critical symptoms

At a time when hospitals around the world are overwhelmed with people with the mutated “Omicron”, and in an attempt to stave off the risk of severe symptoms and death from the virus, the World Health Organization approved, yesterday, Friday, two drugs to treat people with “Covid-19”, added to a set of available means to the side of vaccinations.

The organization earlier predicted that half of Europe’s population will be infected with the virus by March. In their recommendation, which was published in the British Medical Journal “BMG”, the organization’s experts said: The arthritis drug “baricitinib” used with “corticosteroids” to treat “Covid-19” patients with severe or critical symptoms; It improved survival rate and reduced the need for ventilators.

According to the Middle East, experts recommended treatment with industrial antibodies “Sotrovimab” for “Covid-19” patients with non-serious symptoms and at risk of hospitalization, such as the elderly and people with immunodeficiency, or chronic diseases such as diabetes.

The benefits of sotromivab for people not at risk of hospitalization were considered insignificant.

The World Health Organization said: Its efficacy against new mutant such as Omicron is “still not confirmed”, as quoted by Agence France-Presse.

So far, three other treatments for Covid-19 patients have received WHO approval, starting with corticosteroids for acute symptoms in September 2020, and low-cost and widely used corticosteroids to treat infections that usually accompany acute cases.

The two drugs used to treat arthritis patients, tocilizumab and sarilumab, which were recommended by the World Health Organization in July, belong to a family called “interleukin-6 antagonists” or “IL-6 antagonists.” And they fight, like corticosteroids, a wild immune system that appears to be the source of severe forms of Covid-19.

According to the guidelines: “When both are available, a choice is made between them based on factors such as cost and clinical experience.” The WHO approved the synthetic antibody Regeneron in September. The instructions say: Sotrovimab can be used on the same category of patients.

WHO recommendations for the treatment of Covid are updated regularly based on new data from clinical trials.

One of them to treat arthritis .. “World Health” approves two new treatments for “Corona”

already

At a time when hospitals around the world are overwhelmed with people with the mutated “Omicron”, and in an attempt to stave off the risk of severe symptoms and death from the virus, the World Health Organization approved, yesterday, Friday, two drugs to treat people with “Covid-19”, added to a set of available means to the side of vaccinations.

The organization earlier predicted that half of Europe’s population will be infected with the virus by March. In their recommendation, which was published in the British Medical Journal “BMG”, the organization’s experts said: The arthritis drug “baricitinib” used with “corticosteroids” to treat “Covid-19” patients with severe or critical symptoms; It improved survival rate and reduced the need for ventilators.

According to the Middle East, experts recommended treatment with industrial antibodies “Sotrovimab” for “Covid-19” patients with non-serious symptoms and at risk of hospitalization, such as the elderly and people with immunodeficiency, or chronic diseases such as diabetes.

The benefits of sotromivab for people not at risk of hospitalization were considered insignificant.

The World Health Organization said: Its efficacy against new mutant such as Omicron is “still not confirmed”, as quoted by Agence France-Presse.

So far, three other treatments for Covid-19 patients have received WHO approval, starting with corticosteroids for acute symptoms in September 2020, and low-cost and widely used corticosteroids to treat infections that usually accompany acute cases.

The two drugs used to treat arthritis patients, tocilizumab and sarilumab, which were recommended by the World Health Organization in July, belong to a family called “interleukin-6 antagonists” or “IL-6 antagonists.” And they fight, like corticosteroids, a wild immune system that appears to be the source of severe forms of Covid-19.

According to the guidelines: “When both are available, a choice is made between them based on factors such as cost and clinical experience.” The WHO approved the synthetic antibody Regeneron in September. The instructions say: Sotrovimab can be used on the same category of patients.

WHO recommendations for the treatment of Covid are updated regularly based on new data from clinical trials.

January 15, 2022 – Jumada Al-Thani 12 1443

12:44 PM


Based on new data from clinical trials, it benefits patients with severe or critical symptoms

At a time when hospitals around the world are overwhelmed with people with the mutated “Omicron”, and in an attempt to stave off the risk of severe symptoms and death from the virus, the World Health Organization approved, yesterday, Friday, two drugs to treat people with “Covid-19”, added to a set of available means to the side of vaccinations.

The organization earlier predicted that half of Europe’s population will be infected with the virus by March. In their recommendation, which was published in the British Medical Journal “BMG”, the organization’s experts said: The arthritis drug “baricitinib” used with “corticosteroids” to treat “Covid-19” patients with severe or critical symptoms; It improved survival rate and reduced the need for ventilators.

According to the Middle East, experts recommended treatment with industrial antibodies “Sotrovimab” for “Covid-19” patients with non-serious symptoms and at risk of hospitalization, such as the elderly and people with immunodeficiency, or chronic diseases such as diabetes.

The benefits of sotromivab for people not at risk of hospitalization were considered insignificant.

The World Health Organization said: Its efficacy against new mutant such as Omicron is “still not confirmed”, as quoted by Agence France-Presse.

So far, three other treatments for Covid-19 patients have received WHO approval, starting with corticosteroids for acute symptoms in September 2020, and low-cost and widely used corticosteroids to treat infections that usually accompany acute cases.

The two drugs used to treat arthritis patients, tocilizumab and sarilumab, which were recommended by the World Health Organization in July, belong to a family called “interleukin-6 antagonists” or “IL-6 antagonists.” And they fight, like corticosteroids, a wild immune system that appears to be the source of severe forms of Covid-19.

According to the guidelines: “When both are available, a choice is made between them based on factors such as cost and clinical experience.” The WHO approved the synthetic antibody Regeneron in September. The instructions say: Sotrovimab can be used on the same category of patients.

WHO recommendations for the treatment of Covid are updated regularly based on new data from clinical trials.





LEAVE A REPLY

Please enter your comment!
Please enter your name here